Artivion (NYSE:AORT – Get Free Report)‘s stock had its “buy” rating reiterated by Needham & Company LLC in a research report issued to clients and investors on Monday, Marketbeat.com reports. They presently have a $44.00 target price on the stock. Needham & Company LLC’s target price suggests a potential upside of 75.53% from the company’s previous close.
A number of other equities research analysts also recently commented on the company. Weiss Ratings downgraded Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, June 8th. Canaccord Genuity Group restated a “buy” rating and set a $36.00 target price on shares of Artivion in a research report on Tuesday, June 16th. Wall Street Zen cut Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Citizens Jmp cut their price target on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research report on Friday, May 8th. Finally, LADENBURG THALM/SH SH raised shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price objective on the stock in a research note on Friday, April 10th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $44.17.
Get Our Latest Stock Report on Artivion
Artivion Stock Performance
Insider Buying and Selling at Artivion
In other news, SVP Andrew M. Green sold 44,001 shares of the stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total transaction of $910,820.70. Following the completion of the sale, the senior vice president owned 60,259 shares of the company’s stock, valued at $1,247,361.30. This represents a 42.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is owned by company insiders.
Institutional Investors Weigh In On Artivion
Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Artivion by 4.7% in the 4th quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock worth $144,588,000 after purchasing an additional 141,030 shares during the period. Morgan Stanley lifted its holdings in shares of Artivion by 0.8% in the fourth quarter. Morgan Stanley now owns 2,256,742 shares of the company’s stock valued at $102,930,000 after purchasing an additional 18,248 shares in the last quarter. State Street Corp boosted its position in shares of Artivion by 2.9% during the fourth quarter. State Street Corp now owns 1,584,920 shares of the company’s stock worth $72,288,000 after buying an additional 44,641 shares during the period. Fred Alger Management LLC boosted its position in shares of Artivion by 4.2% during the fourth quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock worth $62,603,000 after buying an additional 55,322 shares during the period. Finally, Conestoga Capital Advisors LLC bought a new position in shares of Artivion during the first quarter worth about $43,044,000. 86.37% of the stock is owned by institutional investors.
Artivion Company Profile
Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.
Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.
Featured Articles
- Five stocks we like better than Artivion
- Buyback Boom: These 3 Companies Are Betting Billions on Their Own Stocks
- Costco’s Cooling Comp Sales Keep Stock Stuck in Neutral for Now
- Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
- Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.
